Treatment of Multiple Primary Malignancies With PD-1 Inhibitor Camrelizumab: A Case Report and Brief Literature Review

BACKGROUND: With significant advances in the diagnostic tools and treatment modalities of cancer, the incidence of multiple primary malignancies (MPMs) has increased in the last decades. The therapeutic option changed with the arising of immune checkpoint inhibitors (ICIs), which have improved the s...

Descripción completa

Detalles Bibliográficos
Autores principales: Wan, Yuchen, Wang, Zhixue, Yang, Ning, Liu, Fenye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294358/
https://www.ncbi.nlm.nih.gov/pubmed/35865468
http://dx.doi.org/10.3389/fonc.2022.911961

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294358/
https://www.ncbi.nlm.nih.gov/pubmed/35865468
http://dx.doi.org/10.3389/fonc.2022.911961

Ejemplares similares